Pettit Paul D M, Thompson Jason R, Chen Anita H
Mayo Clinic, Jacksonville, Florida 32224, USA.
Curr Opin Obstet Gynecol. 2002 Oct;14(5):521-5. doi: 10.1097/00001703-200210000-00014.
The first sacral nerve stimulators implanted by Tanagho and Schmidt (1981) were performed for the indications of urinary urge incontinence, urgency-frequency, and nonobstructive urinary retention. Since that time, observations have been made for benefits beyond voiding disorders. These additional benefits have included re-establishment of pelvic floor muscle awareness, resolution of pelvic floor muscle tension and pain, decrease in vestibulitis and vulvadynia, decrease in bladder pain (interstitial cystitis), and normalization of bowel function.
Therapy for fecal incontinence in patients with a structurally intact sphincter mechanism appears to be very promising. Investigators agree that there is a role for sacral nerve stimulation in patients with urge fecal incontinence that have failed conservative efforts. Objective manovolumetric testing shows an increase in resting pressure, an increase in voluntary contraction pressure, a decrease in rectal volumes which cause first urge, a decrease in rectal volume to initiate first urge to defecate, and an increase in duration of maximum squeeze pressure. Intractable interstitial cystitis is defined as patients that have failed conventional therapy. Historically, the only option remaining was extirpative surgery or diversion. Maher et al. reported on patients with intractable interstitial cystitis who had undergone sacral nerve stimulation. They found that 73% of these patients had a reduction in pelvic pain, daytime frequency, nocturnal urgency and an increase in average voided volumes. The final area of interest concerns refractory pelvic pain. Siegal et al. reported a decrease in severity, number of hours of pain, and improved quality of life measures in patients who underwent transforamenal sacral nerve stimulations. These patients had all failed conventional pain therapy.
While the data are encouraging in these new arenas of pelvic floor disorders, investigators acknowledge the need for multicenter, statistically powered studies to evaluate the validity of these findings.
塔纳戈和施密特于1981年首次植入骶神经刺激器,用于治疗尿急失禁、尿频尿急和非梗阻性尿潴留。自那时以来,人们观察到其益处不仅限于排尿障碍。这些额外的益处包括恢复盆底肌肉感知、缓解盆底肌肉紧张和疼痛、减轻前庭炎和外阴痛、减轻膀胱疼痛(间质性膀胱炎)以及使肠道功能正常化。
对于括约肌机制结构完整的大便失禁患者,治疗似乎非常有前景。研究人员一致认为,骶神经刺激对保守治疗无效的急迫性大便失禁患者有作用。客观的测压测试显示静息压力增加、自主收缩压力增加、引起首次便意的直肠容积减小、引发首次排便便意的直肠容积减小以及最大挤压压力持续时间增加。顽固性间质性膀胱炎定义为常规治疗无效的患者。从历史上看,剩下的唯一选择是切除手术或改道。马赫等人报告了接受骶神经刺激的顽固性间质性膀胱炎患者的情况。他们发现,这些患者中有73%的人盆腔疼痛减轻、白天尿频、夜间尿急减轻,平均排尿量增加。最后一个感兴趣的领域是难治性盆腔疼痛。西格尔等人报告说,接受经椎间孔骶神经刺激的患者疼痛严重程度降低、疼痛小时数减少,生活质量指标得到改善。这些患者均常规疼痛治疗无效。
虽然这些关于盆底功能障碍新领域的数据令人鼓舞,但研究人员承认需要进行多中心、有统计学效力的研究来评估这些发现的有效性。